| Previous Close | 23.5 |
| Open | 23.65 |
| Day High | 23.65 |
| Day Low | 21.72 |
| 52-Week High | 35 |
| 52-Week Low | 8.2 |
| Volume | 148,748 |
| Average Volume | 134,625 |
| Market Cap | 173.4M |
| PE | -1.37 |
| EPS | -16.97 |
| Moving Average 50 Days | 26.15 |
| Moving Average 200 Days | 22.2 |
| Change | -0.31 |
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 12, 2025 10:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe e
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and reg